Exhalix
Exhalix LLC is a pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic devices for peripheral artery disease, chronic wounds, and microvascular health, serving vascular surgeons, podiatrists, and diabetic patients through clinical research partnerships pending FDA clearance.
- Company typePrivate
- Founded2012
- HeadquartersAlbuquerque, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Exhalix does
Exhalix LLC is a privately held, pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic technologies for microvascular health. Its portfolio comprises four core technologies: TAGS™, a non-invasive transdermal diagnostic device that measures endogenous H2S emission rates from the skin surface in under 15 minutes to detect peripheral artery disease (PAD); HEALS™, a topical therapeutic device delivering controlled exogenous H2S to chronic wounds using patented electroactive coating technology with dose control to within 10% of target (1-250 nmol/dose); ReLIS™, an implantable device extending the platform to disadvantaged surgical wounds; and Genie:S™, an on-demand, in-situ H2S synthesis and delivery platform. Pre-clinical studies in Sprague-Dawley and Zucker Diabetic rat models have demonstrated strong revascularization, reperfusion rate, and tissue recovery outcomes.
The company targets vascular surgeons, podiatrists, and the broader healthcare ecosystem treating patients with PAD, chronic limb-threatening ischemia (CLTI), and diabetic chronic wounds—an addressable market of more than 6.5 million Americans with combined healthcare costs exceeding $21 billion. The business model is hardware sales of medical devices to enterprise healthcare buyers, but all products remain investigational (TAGS™) or in preclinical animal studies (HEALS™, ReLIS™) pending FDA clearance. Revenue is currently zero, with funding sourced almost entirely from non-dilutive NIH Small Business Innovation Research (SBIR) grants across multiple institutes (NIGMS, NHLBI, NIA, NCATS, NIDDK) and an NSF award totaling $269,999 in 2016. Distribution occurs through clinical partnerships—primarily with UNM School of Medicine and Texas A&M College of Veterinary Medicine—rather than commercial channels. The company is founder-led, with Reza Shekarriz (Founder/CEO, PhD from WSU, post-doc at Johns Hopkins, 25 years of R&D experience) and Robert Beckius (Director of Engineering, 20+ years of device commercialization), operating with 1-10 employees from Albuquerque, NM.
Exhalix firmographics
Firmographics- Name
- Exhalix
- Legal name
- Exhalix LLC
- Website
- https://exhalix-llc.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Exhalix LLC is a pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic devices for peripheral artery disease, chronic wounds, and microvascular health, serving vascular surgeons, podiatrists, and diabetic patients through clinical research partnerships pending FDA clearance.
- Ownership category
- akta.pro rank
Exhalix industry classification
Industry- Product category
- Vascular Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)
- akta.pro secondary industries
- Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC), Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)
Keywords
Where Exhalix is headquartered
LocationHeadquarters
- HQ city
- Albuquerque
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Exhalix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Medical Device Sales: Revenue from sale of diagnostic devices (TAGS™) and therapeutic devices (HEALS™, ReLIS™) for peripheral artery disease and chronic wound treatment. Company is currently in pre-commercial stage with investigational devices undergoing clinical validation for FDA clearance.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Exhalix product offering
Product offeringCore offering
Exhalix develops non-invasive diagnostic and minimally invasive therapeutic medical devices for the detection and treatment of lower extremity microvascular disease. Its TAGS™ device measures transdermal hydrogen sulfide (H2S) emission from skin to detect peripheral artery disease (PAD), while HEALS™ and ReLIS™ deliver controlled, localized H2S therapy to chronic and surgical wounds using proprietary electroactive coating technology.
Product overview
Exhalix develops a portfolio of medical diagnostic and therapeutic products centered on hydrogen sulfide (H2S) technology for microvascular health. The core offerings include: TAGS™ — a non-invasive transdermal diagnostic device that measures H2S emission rates to detect peripheral artery disease; HEALS™ — a topical therapeutic device for chronic wound healing via localized H2S delivery; ReLIS™ — an implantable device for disadvantaged surgical wounds; and Genie:S™ — a platform technology for additional H2S applications. The company employs trace-level gas sensors, microfluidic systems, and microelectronic devices, with electroactive coatings using solid-state metal sulfide technology for controlled H2S synthesis and delivery.
Differentiator
Problem solved
Functional benefit
Brands
- TAGS™: Non-invasive diagnostic device that measures transdermal hydrogen sulfide for evaluation of lower extremity vascular health and diagnosis of peripheral artery disease (PAD).
- HEALS™
- ReLIS™
- Genie:S™
Products and services
- TAGS™ (Transdermal Analyte Gas Sensing) A non-invasive diagnostic device that measures transdermal hydrogen sulfide (H2S) emission rate from the skin surface of the lower extremities in under 15 minutes to evaluate vascular health and detect peripheral artery disease (PAD). Intended for healthcare providers (vascular surgeons, podiatrists, wound care specialists) and currently limited by U.S. Federal law to investigational use pending FDA clearance.
- HEALS™ (Hemodynamic and Endothelial Activation by Localization of Sulfides) A topical medical device for chronic wound application that locally delivers hydrogen sulfide to wounded tissue using patented electroactive coating technology and solid-state metal sulfide coatings, accelerating revascularization and wound healing. Aimed at diabetic and vascular chronic wound patients treated by wound care specialists and vascular surgeons; currently in preclinical development.
- ReLIS™ (Repair by Local Infusion of Sulfides) An implantable therapeutic device built on the same electroactive coating platform as HEALS that delivers sulfides directly to disadvantaged, ischemic surgical wounds to support revascularization and tissue recovery. Intended for surgical patients at risk of wound complications; currently in preclinical animal studies with the UNM School of Medicine.
- Genie:S™ Platform Platform technology for on-demand, in-situ hydrogen sulfide synthesis and delivery using electrolytic technology and solid-state metal sulfide coatings, intended to support additional therapeutic applications of H2S delivery beyond chronic and surgical wounds.
Quantifiable outcome
- Pre-clinical data from Sprague-Dawley (SD) and Zucker Diabetic (ZDF) rats show strong revascularization (Vessel Density), reperfusion rate, and tissue recovery even at highly ischemic conditions
- +1 more outcomes
Companies that use Exhalix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Exhalix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Exhalix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and major.
- Texas A&M College of Veterinary Medicine and Biomedical SciencescoreCollaboration on development of bandage-like device that delivers hydrogen sulfide gas directly to wounds to improve healing. Texas A&M researchers working with Exhalix on preclinical development of wound treatment technology using specialized coating to generate controlled H2S locally at wound site.
- UNM School of MedicinecoreLong-standing clinical partnership for development and testing of TAGS™, HEALS™, and ReLIS™ technologies. Multiple NIH-funded collaborations including Phase I SBIR grants for prototype development, clinical trials, and productization. UNM vascular surgeons and researchers contributing to research on H2S signaling molecule and clinical validation studies.
- TAGS MedicalmajorSpun out from Exhalix LLC in January 2025 for commercialization of TAGS™ technology. Represents dedicated entity for diagnostic device commercialization separate from therapeutic development.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Exhalix competitors and assessment
Company assessmentDirect peers
- Sulfagenix: Clinical-stage biotech developing hydrogen sulfide (H2S) donor therapeutics for cardiovascular and other diseases. Closest scientific peer to Exhalix's H2S-based therapeutic approach, although Sulfagenix uses systemic drug delivery while Exhalix uses device-based local delivery.
- CardieX (parent of AtCor Medical): Develops non-invasive central blood pressure and arterial stiffness assessment devices (SphygmoCor, Conneqt) for cardiovascular disease diagnosis including PAD. Direct functional peer to TAGS™ as a non-invasive vascular diagnostic.
- Itamar Medical (ZOLL Itamar): Develops EndoPAT® for non-invasive endothelial function assessment, directly relevant to Exhalix's core thesis that endothelial dysfunction (H2S-related) is a diagnostic and therapeutic target. Both companies address vascular health via novel biomarkers.
Broad incumbents
- Organogenesis: Leading commercial-stage wound care company with Apligraf® (skin substitute) and other regenerative products. Represents the established wound healing market that HEALS™ would compete in once approved; comparable business model (medical device + biologics for wound healing) but much larger scale and established reimbursement.
- Integra LifeSciences: Diversified medical device company with significant wound care and regenerative tissue franchise (Integra Dermal Regeneration Template). Competes in the same chronic wound and surgical wound healing markets targeted by HEALS™ and ReLIS™.
- MiMedx: Commercial-stage wound care and surgical recovery company with EpiFix® (dehydrated amniotic membrane allograft). Direct competitor in advanced chronic wound treatment market; comparable distribution model through wound care clinics and podiatry.
- Coloplast: Global leader in wound care (Biatain, Comfeel portfolios) and ostomy care. Major incumbent in the chronic wound management market where HEALS™ would compete; provides scale and reimbursement benchmark for wound healing therapeutics.
- Smith+Nephew: Multinational medical device company with substantial advanced wound management franchise (PICO, ACTICOAT, RENASYS). Major incumbent serving vascular surgeons and wound care clinics that would be the initial call point for HEALS™ and ReLIS™.
- ConvaTec: Global medical products company with major advanced wound care portfolio (AQUACEL, Foam Lite). Direct incumbent in the chronic wound care market and comparable customer base (wound care nurses, podiatrists, vascular surgeons).
- Abbott Vascular: Large medical device division offering PAD diagnostic and treatment products. Represents the kind of strategic acquirer or competitor that could partner with or compete against Exhalix in the vascular diagnostic space; comparable end customer (vascular specialists) but vastly broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Exhalix social profiles
Digital presenceExhalix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exhalix leadership team
Management profileNumber of profiles
Profiles2 records
Exhalix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Exhalix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exhalix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exhalix
What does Exhalix do?
Exhalix develops non-invasive diagnostic and minimally invasive therapeutic medical devices for the detection and treatment of lower extremity microvascular disease. Its TAGS™ device measures transdermal hydrogen sulfide (H2S) emission from skin to detect peripheral artery disease (PAD), while HEALS™ and ReLIS™ deliver controlled, localized H2S therapy to chronic and surgical wounds using proprietary electroactive coating technology.
Is Exhalix a public or private company?
Exhalix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Exhalix founded?
Exhalix was founded in 2012. It employs 1 to 10 people.
Where is Exhalix based?
Exhalix is headquartered in Albuquerque, United States, in the North America region.
How does Exhalix make money?
One revenue line is on record: medical Device Sales.
Who are Exhalix's main competitors?
Direct peers on record are Sulfagenix, CardieX (parent of AtCor Medical) and Itamar Medical (ZOLL Itamar). Broad incumbents are Organogenesis, Integra LifeSciences, MiMedx, Coloplast, Smith+Nephew, ConvaTec and Abbott Vascular.
Does Exhalix have an API?
No public API is recorded for Exhalix.
What industry is Exhalix in?
Exhalix's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems), with a secondary code of HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 334510 and its SIC code is 3841.